Research Article

Synergistically Enhanced Mucoadhesive and Penetrable Polypeptide Nanogel for Efficient Drug Delivery to Orthotopic Bladder Cancer

Hui Guo,^{1,2} Faping Li,² Heping Qiu ^{1,2} Weiguo Xu,¹ Pengqiang Li,¹ Yuchuan Hou,² Jianxun Ding,¹ and Xuesi Chen¹

¹Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, China

²Department of Urinary Surgery, The First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, China

Correspondence should be addressed to Jianxun Ding; jxding@ciac.ac.cn

Received 11 May 2019; Accepted 26 March 2020; Published 3 August 2020

Copyright © 2020 Hui Guo et al. Exclusive Licensee Science and Technology Review Publishing House. Distributed under a Creative Commons Attribution License (CC BY 4.0).

Intravesical chemotherapy has been recommended after the gold standard of transurethral resection of the bladder tumor to prevent bladder cancer (BC) from local recurrence in the clinic. However, due to rapid urine excretion and barrier protection of the bladder wall, the clinical performances of chemotherapeutic drugs are severely compromised. In the present work, a smart positively charged disulfide-crosslinked nanogel of oligoarginine-poly(ethylene glycol)-poly(L-phenylalanine-co-L-cystine) (R_9 -PEG-P(LP-co-LC)) was prepared to prolong the retention period and enhance the penetration capability of chemotherapeutic agent toward the bladder wall. PEG significantly improved the aqueous dispersibility of the 10-hydroxycamptothecin (HCPT)-loaded R_9 -PEG-P(LP-co-LC) (*i.e.*, R_9 NG/HCP) and enhanced the mucoadhesive capability by the nonspecific interaction between PEG chain and the bladder mucosa accompanied with the electrostatic interaction between the cationic R_9 and negatively charged bladder mucosa. Besides, R_9 , as a cell-penetrating peptide, efficiently penetrated through the cell membrane and delivered carried cargo. The disulfide bond endowed the selective release behavior of HCPT triggered by the intracellular reductive microenvironment. As an advanced chemotherapeutic nanoformulation, the smart R_9 NG/HCP demonstrated superior cytotoxicity against human BC 5637 cells *in vitro* and remarkably enhanced tumor suppression activity toward orthotopic BC models of mouse and rat *in vivo*, indicating its great potential in the clinical intravesical BC chemotherapy.

1. Introduction

Costs of curing bladder cancer (BC) are the highest on a per-patient basis because of the elevated rate of recurrence and multiple therapeutic interventions [1]. Over 75% of BC cases are initially diagnosed with non-muscle-invasive bladder cancer (NMIBC) [2]. The recommendation for NMIBC patients after transurethral resection of the bladder tumor is immediate intravesical chemotherapy, which has been proven to help prevent cancer from recurrence [3]. However, the clinical performances of chemotherapeutic drugs are severely compromised by rapid urine excretion and barrier protection of the bladder wall. Approximately 75% of patients will experience tumor relapse or progression within five years, which significantly affects their survival [4]. The five-year survival rate of BC patients has not been improved in the past three decades [5].

Nanomedicine, as revolutionary manufacturing technology, is expected to provide great opportunities to upregulate the exposure periods of drugs within the bladder. Currently, the leading materials, such as poly(ethylene glycol) (PEG) [6], chitosan [7], and liposomes [8], have been developed to improve the mucoadhesiveness or penetrability. PEG seems to be the most promising mucoadhesive polymer due to the nonspecific interaction between PEG chain and mucous membrane [9]. Moreover, PEG possesses the capability of improving the water solubility of hydrophobic drugs [10] and is well known for its reduced toxicity and low immunogenicity [11]. Cell-penetrating peptides (CPPs) are potentially less cytotoxic and possess the capacity of permeating through cell membrane to transport carried cargoes [12, 13]. The combination of CPPs with anti-tumor drugs has been considered an incredibly attractive concept to improve

therapeutic efficacy [14]. Among them, the arginine-rich CPPs have been demonstrated to be highly efficient in terms of cell uptake, especially the oligoarginine of nine arginine residues (R_9) [15, 16].

Accordingly, an innovative nanogel of R_9 -poly(ethylene glycol)-poly(L-phenylalanine-co-L-cystine) (R_9 -PEG-P(LP-co-LC)) was successfully synthesized to improve the mucoadhesiveness and penetrability of chemotherapeutic drugs (Scheme 1A). 10-Hydroxycamptothecin (HCPT) was applied as a model drug and encapsulated into the core of R_9 -PEG-P(LP-co-LC) by facile diffusion. The obtained drug-loaded nanogel was referred as R_9 NG/Hcpt. The morphology of R_9 NG/Hcpt is similar to that of an octopus with spears in its hands, as shown in Scheme 1B. The rinsing of R_9 NG/Hcpt caused by urine excretion was resisted by the presence of PEG chains, which were like arms of an octopus, and R_9 , which enhanced the mucoadhesion of R_9 NG/Hcpt through the nonspecific and electrostatic interactions, respectively. The powerful penetrating capacity of R_9 overcame barrier protection of the bladder wall. R_9 was the weapon in the hands of octopus to break through obstacles. The drug-loaded core of polypeptide nanogel was much like the head of the octopus, which released the cargo triggered by the high concentration of glutathione (GSH) in BC cells [17].

The mucoadhesive nanogel (*i.e.*, PLL-P(LP-co-LC)) reported previously was synthesized by the ring-opening polymerization (ROP) of $N(\epsilon)$ -benzyloxycarbonyl-L-lysine N -carboxyanhydride (ZLL NCA), L-phenylalanine N -carboxyanhydride (LP NCA), and L-cystine N -carboxyanhydride (LC NCA) [18]. The nanogel reported in this work, as distinct from PLL-P(LP-co-LC), introduced PEG and R_9 and further magnified the mucoadhesion and penetration of R_9 NG/Hcpt as a benefit of the synergistic effect of PEG and R_9 .

The nanogel composed of PEG and polypeptide, but without R_9 , was synthesized as a negative control (*i.e.*, NG/Hcpt). In order to better understand the anti-tumor efficacy of R_9 NG/Hcpt *in vivo*, different orthotopic BC models of mouse and rat were constructed. The orthotopic BC model in mouse was constructed by instilling MB49 cells into the bladder that was pretreated with PLL solution [19]. The orthotopic BC model in rat was successfully established by intravesical instillation of N -methyl- N -nitrosourea (MNU). MNU played a vital role in the process of carcinogenesis, which was histologically indistinguishable from the human tumor [20]. The physicochemical properties, intracellular release profiles, and cytotoxicity of R_9 NG/Hcpt *in vitro* and mucoadhesiveness, permeability, biodistribution, anti-tumor activity, and systemic toxicity *in vivo* were systematically demonstrated. Encouragingly, R_9 NG/Hcpt possessed unique physicochemical properties to improve the chemotherapy efficacy of BC both *in vitro* and *in vivo*, as a potential benefit of strong urothelium adhesive property, high penetrating capacity, and selective drug release behavior.

2. Results and Discussion

2.1. Preparation and Characterizations of Empty and HCPT-Loaded R_9 -PEG-P(LP-co-LC). aPEG-P(LP-co-LC) was syn-

thesized by the ROP of LP NCA and LC NCA with the amino-terminated allyloxy poly(ethylene glycol) (aPEG-NH₂) as a macroinitiator. R_9 -PEG-P(LP-co-LC) was synthesized by the decoration of R_9 at the end of PEG by sequential deprotection, amidation, and Michael addition reactions, as depicted in Scheme 1A. The chemical structures of intermediates and the desired product R_9 -PEG-P(LP-co-LC) were confirmed by the proton nuclear magnetic resonance (¹H NMR) spectra. The characteristic resonance signals at 7.19 ppm (e; -CH₂C₆H₅, 5H) and 3.46 ppm (d; -CH₂C₆H₅, 2H) were assigned to the protons in the L-phenylalanine unit. The peak at 2.42 ppm (g; -SCH₂-, 2H) was ascribed to protons of the L-cystine unit. The signal at 4.55 ppm (c+f; -COCH(CH₂)NH-, 1H) was attributed to the protons of peptide backbone both in the polypeptide and R_9 . The strong and broad signal peak of b at 3.82 ppm (b; -OCH₂CH₂-, 4H) was assigned to the methylene protons of PEG. The signal at 2.42 ppm (a; -SCH₂CH₂CH₂-, 2H) was produced by the thiol-ene click reaction between allyloxy and thiol groups. The peaks at 5.28 and 5.82 ppm (a and b; CH₂=CH-, 2H and 1H, respectively) were attributed to the allyloxy protons of aPEG-P(LP-co-LC), as shown in Supplementary Figure S1. The signal disappearance of the allyloxy protons (i) and the appearance of the *t*-butyloxycarbonyl (*t*-Boc) resonance signal at 1.52 ppm (j; (CH₃)₃C-, 9H) indicated the successful synthesis of *t*-Boc-NH-PEG-P(LP-co-LC), as depicted in Supplementary Figure S2. The disappearance of *t*-Boc peak (j) demonstrated the successful synthesis of NH₂-PEG-P(LP-co-LC), as shown in Supplementary Figure S3. The maleimide-terminated polymer was produced by a simple amidation reaction, which was confirmed by the signal at 6.48 ppm (h; -CH=CH-, 2H), as shown in Supplementary Figure S4B. The representative peaks at 1.4–4.2 ppm in Supplementary Figure S4C matched precisely to the signals in Supplementary Figure S4A, and the signal disappearance of two vinyl protons on maleimide at 6.48 ppm (h) both confirmed the successful synthesis of R_9 -PEG-P(LP-co-LC). The nanogel of Mal-PEG-P(LP-co-LC) was synthesized as a negative control. The molar ratio of LP and LC in R_9 -PEG-P(LP-co-LC) was calculated as 9:5 according to the content of carbon (C), hydrogen (H), nitrogen (N), and sulfur (S) determined by elemental analysis.

The drug loading contents (DLCs) of R_9 NG/Hcpt and NG/Hcpt were up to 26.2 ± 0.3 and 25.6 ± 0.4 wt.%, respectively. The drug loading efficiencies (DLEs) of R_9 NG/Hcpt and NG/Hcpt were 88.9 ± 1.4 and 86.0 ± 1.6 wt.%, respectively. As depicted in Figure 1(a), the resulting R_9 NG/Hcpt displayed spherical morphology, which was detected by transmission electron microscopy (TEM). The hydrodynamic radius (R_h) of R_9 NG/Hcpt in phosphate-buffered saline (PBS) at pH 7.4 was 48.9 ± 0.7 nm, while that of NG/Hcpt was detected to be 44.8 ± 1.3 nm (Figure 1(b)). Even when incubated with PBS for 48 h, sizes of R_9 NG/Hcpt and NG/Hcpt almost maintained constant. However, after co-incubation with 10.0 mM D,L-1,4-dithiothreitol (DTT) for 24 h, the R_h of NG/Hcpt increased to 401.0 ± 50.3 nm, and that of R_9 NG/Hcpt increased to 566.7 ± 20.6 nm, which could not be detected after 24 h

SCHEME 1: Synthesis and *in vivo* metabolism of water-soluble mucoadhesive nanogel. (A) Synthesis route of R_9 -PEG-P(LP-co-LC). (B) Schematic illustration for self-assembly of R_9 NG/Hcpt, intravesical chemotherapy of R_9 NG/Hcpt, superior mucoadhesiveness, enhanced penetrability, selective accumulation in tumor tissue, promoted internalization, and accelerated Hcpt release from R_9 NG/Hcpt.

FIGURE 1: Characterizations of R₉NG/HCPT. (a) Morphologies of R₉NG/HCPT in PBS by TEM. (b) R_h of R₉NG/HCPT in PBS. (c) Stability of R₉NG/HCPT in PBS without or with 10.0 mM DTT versus time. The scale bar in (a) represents 100 nm. // represents the interruption of R_h -related light-scattering signal. (d) *In vitro* release profiles of R₉NG/HCPT. All the statistical data are represented as mean $\pm$ standard deviation ($n = 3$).

(Figure 1(c)). The results demonstrated the reduction-responsive properties of NG/HCPT and R₉NG/HCPT, which were critical for the selective delivery of drugs to cancer cells.

The zeta potential of NG/HCPT was -17.3 ± 0.8 mV, while that of R₉NG/HCPT was 26.9 ± 1.2 mV. The positive charge of R₉NG/HCPT further demonstrated the successful conjugation of R₉ onto the surface of the nanogel, which could enhance the interaction between R₉NG/HCPT and negatively charged cell membrane and subsequently upregulated cell internalization [21]. The release behavior of HCPT from R₉NG/HCPT was examined in PBS at pH 7.4 with 0.1% (W/V) Tween-80 containing different concentrations of DTT. As shown in Figure 1(d), free HCPT displayed a

rapid diffusion from the dialysis membrane within 12 h. In contrast, R₉NG/HCPT released only 38.2% of HCPT throughout 72 h in PBS without DTT, demonstrating excellent stability of R₉NG/HCPT under physiological conditions. In addition, the release rate of HCPT from R₉NG/HCPT was remarkably accelerated due to the increased concentration of DTT. The cumulative release amount of HCPT was 62.9% and 94.5% over a period of 72 h with the concentration of DTT ranging from 5.0 to 10.0 mM, respectively. The results demonstrated the excellent physiological stability of R₉NG/HCPT. However, the disulfide bond could be rapidly broken in the reductive microenvironment, resulting in the selective HCPT release in the cancer cells.

2.2. Intracellular Release and Cytotoxicity of R_9 NG/Hcpt.

The intracellular release behavior of R_9 NG/Hcpt was qualitatively evaluated by confocal laser scanning microscopy (CLSM). Figure 2(a) presents the CLSM images of human BC 5637 cells after co-incubation with free HCPT, NG/Hcpt, or R_9 NG/Hcpt with equivalent HCPT concentration at $1.25 \mu\text{g mL}^{-1}$. The cells depicted slightly weaker HCPT fluorescence after co-incubation with R_9 NG/Hcpt for 2 h as compared with that of free HCPT. At the same point, the fluorescence intensity of negatively charged NG/Hcpt was the weakest. Although it was not as simple as small-molecule drugs entering cells by diffusion, the results demonstrated that R_9 NG/Hcpt could be internalized by human BC 5637 cells effectively [22]. Furthermore, after the co-incubation period increased up to 6 h, the cells treated with R_9 NG/Hcpt exhibited more robust HCPT fluorescence than that of free HCPT or NG/Hcpt (Figure 2(a)). The significantly enhanced HCPT fluorescence mainly benefited from the electrostatic interaction between the positively charged R_9 NG/Hcpt and the negatively charged cell membrane [23]. The conjugated R_9 facilitated the cell uptake of R_9 NG/Hcpt through the CPP-mediated cell entry [24]. In addition, the high concentration of GSH in human BC 5637 cells led to the rupture of the disulfide bond and accelerated the HCPT release from R_9 NG/Hcpt [25].

The cell uptake and subsequent release profiles were investigated quantitatively according to the protocol described by Wei et al. [26]. Compared with free HCPT, the cells co-cultured with R_9 NG/Hcpt displayed a slightly lower content of HCPT at 2 h. The accumulation of HCPT in cells co-cultured with NG/Hcpt was the lowest at the same time point. With the prolongation of co-incubation time, the endocytosis of R_9 NG/Hcpt increased significantly, and a relatively higher content of HCPT was maintained as compared to that of free HCPT or NG/Hcpt from the second time point. Conversely, the increased HCPT concentration in the cells of the R_9 NG/Hcpt group was about 1.9 times compared with that in the cells treated with free HCPT (Figure 2(b)), while it was about 1.5 times as much as that in the NG/Hcpt group at 6 h. The results were consistent with the representative finding by CLSM (Figure 2(a)).

To evaluate the potential cytotoxicity of R_9 NG/Hcpt against human BC 5637 cells, a standard methyl thiazolyl tetrazolium (MTT) assay was performed. The cytotoxicity of free HCPT, NG/Hcpt, and R_9 NG/Hcpt was enhanced in a concentration-dependent manner (Figure 2(c)). Furthermore, the cytotoxicity of R_9 NG/Hcpt surpassed those of free HCPT and NG/Hcpt against human BC 5637 cells. The superior cytotoxic effect of R_9 NG/Hcpt probably benefited from the weak positive surface, R_9 , and the reduction-responsive property of R_9 NG/Hcpt, which led to the promoted cell uptake and accelerated intracellular HCPT release in human BC 5637 cells. Importantly, the half-maximal inhibitory concentration (IC_{50}) of R_9 NG/Hcpt was $2.4 \pm 0.1 \mu\text{g mL}^{-1}$, which was lower in comparison with those of free HCPT (*i.e.*, $8.7 \pm 0.8 \mu\text{g mL}^{-1}$) and NG/Hcpt (*i.e.*, $4.7 \pm 0.2 \mu\text{g mL}^{-1}$). The lowest IC_{50} indicated the potent cytotoxicity of R_9 NG/Hcpt quantitatively, suggesting the superiority of R_9 NG/Hcpt for intravesical chemotherapy of BC *in vivo*.

The R_9 NG/Hcpt-induced apoptosis of human BC 5637 cells was measured by flow cytometry (FCM) analysis. As shown in Figure 2(d), the 24 h exposure to three different formulations of HCPT at an equivalent HCPT dosage of $0.1 \mu\text{g mL}^{-1}$ resulted in a noticeable difference in the percentage of apoptotic cells. R_9 NG/Hcpt contributed most to an abundance of apoptotic cells. The total percentage of apoptotic cells was 22.5%, which was constituted with 16.5% early apoptotic cells and 6.0% late apoptotic cells. In contrast, the total percentage of cells displaying apoptosis was reduced to 12.2% and 18.7% after co-incubation with free HCPT and NG/Hcpt, respectively. The results were consistent with the cytotoxicity of R_9 NG/Hcpt described above. When the co-incubation time was prolonged to 48 h, the differences among free HCPT, NG/Hcpt, and R_9 NG/Hcpt groups varied greatly, as shown in Supplementary Figure S5. The total percentage of cells displaying apoptosis was increased to 38.9%, 53.5%, or 63.0% after co-incubation with free HCPT, NG/Hcpt, or R_9 NG/Hcpt, respectively. This phenomenon indicated that different formulations induced the apoptosis of human BC 5637 cells in a time-dependent manner. The increased apoptotic activity induced by R_9 NG/Hcpt benefited from the high intracellular concentration of HCPT, which was internalized through CPP-mediated endocytosis and triggered to release by GSH rapidly.

2.3. Mucoadhesiveness, Permeability, and Biodistribution of R_9 NG/Hcpt.

CLSM was employed to demonstrate the mucoadhesiveness and permeability of R_9 NG/Hcpt. The male Sprague-Dawley (SD) rats with BC were anesthetized and then administrated with different HCPT formulations at a consistent HCPT dosage of 6.0 mg per kg body weight (mg (kg BW)^{-1}) through bladder irrigation. At different indicated time points (*i.e.*, 0.5, 2, 6, 12, 24, and 48 h), the bladders were removed and sectioned.

As depicted in Figure 3(a), the fluorescence signals of free HCPT and R_9 NG/Hcpt were observed in the bladder sections at the first few time points. The fluorescence intensity of R_9 NG/Hcpt was stronger than that of free HCPT. The highest fluorescence signal was observed in the bladder treated with R_9 NG/Hcpt at 0.5 h. Not surprisingly, the fluorescence intensity of R_9 NG/Hcpt decreased over time. However, it remained at a relatively high concentration even at 12 h, indicating the high mucoadhesion of R_9 NG/Hcpt toward the urothelial surface. On the contrary, the fluorescence signal in the bladder exposed to free HCPT decreased rapidly, which was attributed to the continuous excretion of urine. This phenomenon demonstrated the outstanding mucoadhesiveness of R_9 NG/Hcpt. In order to quantitatively prove the mucoadhesiveness of R_9 NG/Hcpt, the average optical density of HCPT was measured. As verified in Figure 3(b), the fluorescence intensity of R_9 NG/Hcpt was 1.6 times higher as compared with that of free HCPT at 0.5 h. Inspiringly, the fluorescence intensity increased from 2.2 to 4.8 times when the retention time was prolonged from 2 to 6 h. The outstanding mucoadhesiveness of R_9 NG/Hcpt benefited from the nonspecific interaction between PEG chain and the bladder mucosa and electrostatic interaction between terminal cationic R_9 and negatively charged surface

FIGURE 2: *In vitro* cell uptake and cytotoxicity. (a) Representative CLSM images of human BC 5637 cells incubated with free HCPT, NG/HCPT, or R_9 NG/HCPT for 2 or 6 h. The blue color was HCPT fluorescence in cells (left). Differential interference contrast (DIC) was used to obtain the bright-field images (middle), and the merged images were shown on the right. The scale bar represents 50 μ m. (b) Intracellular HCPT release profiles in human BC 5637 cells after co-incubation with free HCPT, NG/HCPT, or R_9 NG/HCPT. Data are presented as mean $\pm$ standard deviation ($n = 3$; * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$). (c) The viability of human BC 5637 cells incubated with free HCPT, NG/HCPT, or R_9 NG/HCPT at different concentrations for 24 h. Data are presented as mean $\pm$ standard deviation ($n = 3$; * $P < 0.05$, ** $P < 0.01$). (d) Apoptotic cell populations were calculated by FCM analysis after co-incubating human BC 5637 cells with PBS as a control, free HCPT, NG/HCPT, or R_9 NG/HCPT for 24 h. The lower-left (Q3), lower-right (Q4), upper-right (Q1), and upper-left (Q2) quadrants in each panel indicated the populations of healthy, early and late apoptotic, and necrotic cells, respectively.

FIGURE 3: Mucoadhesiveness. (a) The fluorescence intensities of free HCPT and R₉NG/HCPT adhered to the inner surface of the bladders were determined by CLSM. (b) Quantitative evaluation of HCPT fluorescence intensities from results by CLSM. The scale bar in (a) represents 100 μm . Data are presented as mean $\pm$ standard deviation ($n = 3$; *** $P < 0.001$).

of the bladder mucosa, which retarded the wash-off of R_9 NG/HCPT by urine [27, 28].

The permeability of R_9 NG/HCPT was verified in Figure 4(a). Within half an hour, a much stronger fluorescence signal was observed in the full-thickness bladder wall treated with free HCPT and especially confined to the mucous membrane. At the same time, R_9 NG/HCPT displayed a shallow penetration within the bladder wall. However, R_9 NG/HCPT gradually penetrated through the full-thickness bladder over time. It also maintained a relatively stronger HCPT fluorescence than free HCPT for an extended period. The results indicated the exceptional permeability and accumulation of R_9 NG/HCPT in the bladder. For detailed analysis of the permeability of R_9 NG/HCPT, the HCPT fluorescence signals were normalized to the maximum value. As shown in Figure 4(b), the fluorescence intensity of R_9 NG/HCPT gradually spread throughout the whole bladder tissue over time and remained a comparatively higher HCPT content. The phenomenon was mainly due to the strong penetration ability of R_9 with a positive surface charge [29, 30]. In addition, the advanced mucoadhesiveness of R_9 NG/HCPT further promoted its permeability. An excellent chemotherapeutic effect of R_9 NG/HCPT was predictable based on superior permeability, which was vital for the treatment of BC.

The bladder accumulation of R_9 NG/HCPT was verified by high-performance liquid chromatography (HPLC). Male SD rats were administrated with intravesical instillation of different HCPT solutions, and the experimental rats were euthanized at 6 h. Subsequently, the bladders and other major organs, such as the heart, liver, spleen, lung, and kidney, were excised and homogenized. Then, the samples were extracted with the organic phase of methanol and acetonitrile (1/1, V/V). 20.0 μ L of mixture suspension collected by centrifugation was analyzed for the determination of drug content. HCPT, released from R_9 NG/HCPT, was mainly accumulated in the bladder, which was 2.2 times higher as compared with free HCPT (Figure S6, Supporting Information). In addition, the other organs provided extremely low drug content. The results confirmed the advanced mucoadhesiveness of R_9 NG/HCPT and predicted an improved anti-tumor efficacy of R_9 NG/HCPT with reduced toxicity on normal organs.

2.4. In Vivo Anti-Tumor Efficacy of R_9 NG/HCPT. The anti-tumor efficacy of R_9 NG/HCPT was assessed on the orthotopic BC in C57Bl/6 mice. Briefly, PLL (100.0 μ L of 0.1 mg mL⁻¹ for 20 min) was used to disrupt the glycosaminoglycan layer. 50.0 μ L of MB49 cell suspension, including 1.0×10^5 cells, was slowly injected into the bladder of C57Bl/6 mouse, and the cells were allowed to dwell in the bladder for 50 min [31]. The tumor-bearing mice were randomly divided into four groups: PBS as a control, free HCPT, NG/HCPT, and R_9 NG/HCPT ($n = 6$). Different HCPT formulations were administered weekly by catheterization at a dosage of 6.0 mg (kg BW)⁻¹ for a total of four treatments. To define the development of BC, especially the tumor size, cystography was performed. Polypoid filling defects and irregular surface were manifested in cystography after treat-

ment, which was depicted in Figure 5(a). The most extensive space-occupying lesion was identified in the bladder exposed to PBS, while there was no significant abnormality recognized in the bladder administrated with R_9 NG/HCPT based on the smooth margin. The superior anti-tumor efficacy of R_9 NG/HCPT was intuitively approved by cystography. The result was mostly attributed to the presence of PEG and R_9 in R_9 NG/HCPT, which could eventually result in a remarkably enhanced mucoadhesiveness and permeability to improve the anti-tumor efficacy synergistically. The sub-optimal BC growth inhibition of free HCPT was caused by rapid drug excretion from urine.

The anti-tumor efficacy of R_9 NG/HCPT was further assessed on another orthotopic BC in male SD rats. The orthotopic BC was established by four doses of MNU [32]. Histopathological analysis was performed to demonstrate the successful induction of BC after the intravesical instillation of MNU for eight weeks. As verified in Supplementary Figure S7A, the abundance of cancer cells was observed with apparent architectural disarray and nuclear atypia, indicating the occurrence of BC. The BC-bearing rats were randomly divided into three groups: PBS as a control, free HCPT, and R_9 NG/HCPT ($n = 8$). The equivalent HCPT dosage of 6.0 mg (kg BW)⁻¹ was given by intravesical instillation weekly for a total of six treatments. Cystography was performed to define the development of BC. As pointed in Supplementary Figure S7B, the results were consistent with those of cystography in mice (Figure 5(a)).

The bladders were harvested at the end of the treatments to assess the external surface, which was shown in Figure 5(b) and Figure S7B, Supporting Information. A rigid-walled bladder with the largest volume was detected in the PBS group, suggesting that exuberant growth of the tumor had infiltrated the muscular layer of the bladder wall. In contrast, a smooth-surfaced bladder with standard size and general shape occurred in the R_9 NG/HCPT group. The bladders exposed to free HCPT or NG/HCPT were generally less rigid, suggesting that free HCPT and NG/HCPT were effective but less effective than R_9 NG/HCPT. To be better informed of the growth of the tumor, the bladders were opened up, and the internal surface was displayed (Figure 5(b) and Figure S7B, Supporting Information). Multiple neoplasms with a “fish flesh” soft tan appearance were found in the bladder cavity of the control group, while there was no obvious abnormality in the bladder treated with R_9 NG/HCPT. The bladder observation intuitively confirmed that R_9 NG/HCPT possessed an excellent anti-tumor efficacy on BC both in mouse and rat.

In order to evaluate the systemic toxicity of R_9 NG/HCPT, the body weights of the experimental animals were monitored once a week and shown in Figure 5(c) and Figure S7C, Supporting Information. The experimental animals administrated with R_9 NG/HCPT showed a stable increase in body weight during the treatment, indicating negligible systemic toxicity of R_9 NG/HCPT. Another essential pre-dictor of efficacies and toxicity of various drug formulations was the survival rate, which was shown in Figure 5(d) and Figure S7D, Supporting Information [33]. Different HCPT formulations extended the overall survivals

FIGURE 4: Penetrability. (a) Penetration depth of free HCPT and R₉NG/HCPT was observed by CLSM. (b) Bladder penetration quantification of HCPT fluorescence intensity. The arrow represents the direction of HCPT penetration. The scale bar in (a) represents 100 μ m. M, mucous membrane; S, serous membrane.

FIGURE 5: *In vivo* anti-tumor efficacy on orthotopic BC in C57Bl/6 mice. (a) Cystography and (b) external and internal surface of bladders after intravesical chemotherapy with PBS as a control, free HCPT, NG/HCPT, or R₉NG/HCPT. (c) Evolution of body weight and (d) survival rate during the experiments. The scale bars represent (a) 1.0 cm and (b) 0.5 cm, respectively. Data are presented as mean $\pm$ standard deviation ($n = 6$).

of experimental animals in comparison with the control group. Intravesical instillation of R₉NG/HCPT has shown an especially significant survival advantage in the murine orthotopic BC model. These encouraging results benefited from the excellent biochemical properties of R₉NG/HCPT. R₉NG/HCPT possessed improved mucoadhesiveness and permeability and could selectively release HCPT within cancer cells. All these results suggested that the tumor growth inhibition effect was enhanced, while the systemic toxicity was decreased, which confirmed the reliable biological safety of R₉NG/HCPT.

To further accurately evaluate the anti-tumor activity of R₉NG/HCPT, the histopathological examination of the

bladders was performed after the completion of intravesical chemotherapy. For hematoxylin and eosin (H&E) staining (Figure 6(a) and Figure S8A, Supporting Information), large amounts of cancer cells with spherical or spindle nuclei and prominent atypia were observed in the bladder section of the PBS group. Fortunately, the tumor cells showed karyopyknosis, chromatic agglutination, apoptotic body, and ill-defined morphology in the bladder administrated with R₉NG/HCPT, indicating the predominant contribution of R₉NG/HCPT in tumor suppression.

Moreover, the detection of apoptotic DNA fragments was performed using the terminal deoxyribonucleotide transferase (TdT)-mediated biotin-16-dUTP nick-end labeling

FIGURE 6: Histopathology and immunofluorescence of orthotopic BC in C57Bl/6 mice. (a) Histopathological (*i.e.*, H&E), (b) apoptosis (*i.e.*, TUNEL), and (c) immunofluorescence (*i.e.*, caspase-3 and Ki-67) analysis of tumor tissue sections after treatment with PBS as a control, free HCPT, NG/HCPT, or R₉NG/HCPT. The scale bars in (a), (b), and (c) represent 50 μ m. The quantitative analysis of (d) caspase-3 and (e) Ki-67 expression after treatments with different HCPT formulations. Data are presented as mean $\pm$ standard deviation ($n = 3$; * $P < 0.05$, *** $P < 0.001$).

(TUNEL) method. As depicted in Figure 6(b), the red fluorescence of Cy3 was observed in all the bladder sections. In particular, the bladder treated with R₉NG/HCPPT showed a larger area of flake-like red fluorescence as compared to those of the other three groups.

Caspase-3, a crucial mediator of programmed cell apoptosis, is located downstream of apoptotic response [34]. To further analyze the apoptosis mediated by R₉NG/HCPPT, immunofluorescence staining for caspase-3 was performed. The expression of caspase-3 in mouse and rat bladder tissues was depicted in Figure 6(c) and Figure S8B, Supporting Information, respectively. The level of caspase-3 was much higher in the section administrated with R₉NG/HCPPT as compared to that administrated with free HCPT or NG/HCPPT. A feeble positive signal was observed in the bladder section of control group. The phenomenon indicated that a large number of cells were undergoing apoptosis in the R₉NG/HCPPT group.

Ki-67, a cell proliferative marker, is expressed from prophase to anaphase [35]. To confirm the cell proliferation status after treatment with R₉NG/HCPPT, the expression of Ki-67 in different experimental animals was monitored by immunofluorescence, as shown in Figure 6(c) and Figure S8B, Supporting Information. The strongest positive signal was recorded in the control group. The proportion of Ki-67-positive cells diminished significantly due to the use of different HCPT formulations, especially R₉NG/HCPPT, which demonstrated that the growth of BC cells was obviously suppressed by R₉NG/HCPPT.

To further confirm the expression of caspase-3 and Ki-67, the quantitative analysis was performed by a similar method as mucoadhesiveness mentioned above. The quantitative data described the order of caspase-3 expression as R₉NG/HCPPT > NG/HCPPT > free HCPT > PBS as a control. More importantly, the expression of caspase-3 in the R₉NG/HCPPT group was 7.0 (Figure 6(d), BC in mouse) and 5.6 (Figure S8C, BC in rat) times higher as compared to that of the free HCPT group, which demonstrated that a large number of cells were undergoing apoptosis in the R₉NG/HCPPT group. The quantitative data of Ki-67 demonstrated that the Ki-67 signal was sorted as PBS as a control > free HCPT > NG/HCPPT > R₉NG/HCPPT, demonstrating a significant proliferation inhibition of tumor cells induced by R₉NG/HCPPT (Figure 6(e) and Figure S8D, Supporting Information). All these results indicated that R₉NG/HCPPT possessed unique advantages for BC chemotherapy.

3. Conclusion

In summary, a cationic R₉-decorated disulfide-crosslinked R₉NG/HCPPT with enhanced mucoadhesion and penetration toward the bladder mucosa was designed and developed for intravesical chemotherapy. PEG and R₉ endowed R₉NG/HCPPT with upregulated mucoadhesiveness by the nonspecific and electrostatic interactions, respectively, and R₉ further promoted the permeability of laden nanogel within the bladder wall. The advanced properties of R₉NG/HCPPT overcame the disadvantages of clinical chemotherapeutic drugs, which will bring unpredictable benefits to BC patients and

increase overall survival. More importantly, the reduction-responsive property enabled R₉NG/HCPPT to release the cargo specifically in cancer cells triggered by the intracellular reductive microenvironment. This means that R₉NG/HCPPT may achieve the same intracellular drug concentration as clinical chemotherapeutic agents, but the administered quantity of R₉NG/HCPPT will decrease. The property avoided the potential risk of drug resistance due to high-dose chemotherapy, which was fundamentally critical for patients with BC. The extremely outstanding anti-tumor efficacy and the negligible systemic toxicity pave the way of R₉NG/HCPPT for further progress in the clinical applications.

Data Availability

All data are available in the manuscript and supplementary materials, or from the authors.

Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgments

The study was financially supported by the National Natural Science Foundation of China (Grant Nos. 51973216, 51873207, 51833010, and 51803006), the Science and Technology Development Program of Jilin Province (Grant No. 20200404182YY), and the Youth Innovation Promotion Association of Chinese Academy of Sciences (Grant No. 2019005).

Supplementary Materials

Supplementary 1. Materials and Methods. Supplementary 2. Figure S1: ¹H NMR spectrum of aPEG-P(LP-co-LC) in deuterated trifluoroacetic acid (TFA-*d*). Supplementary 3. Figure S2: ¹H NMR spectrum of *t*-Boc-NH-PEG-P(LP-co-LC) in deuterated trifluoroacetic acid (TFA-*d*). Supplementary 4. Figure S3: ¹H NMR spectrum of NH₂-PEG-P(LP-co-LC) in deuterated trifluoroacetic acid (TFA-*d*). Supplementary 5. Figure S4: ¹H NMR spectra of (A) R₉-PEG-P(LP-co-LC), (B) Mal-PEG-P(LP-co-LC), and (C) R₉C in deuterated trifluoroacetic acid (TFA-*d*). Supplementary 6. Figure S5: FCM analysis calculated apoptotic cell populations after co-incubating human BC 5637 cells with PBS as a control, free HCPT, NG/HCPPT, or R₉NG/HCPPT for 48 h. The lower-left (Q3), lower-right (Q4), upper-right (Q1), and upper-left (Q2) quadrants in each panel indicated the populations of healthy, early and late apoptotic, and necrotic cells, respectively. Supplementary 7. Figure S6: *In vivo* biodistribution of free HCPT and R₉NG/HCPPT. Data are presented as mean ± standard deviation (*n* = 3; ***P* < 0.01). Supplementary 8. Figure S7: *In vivo* anti-tumor efficacy on orthotopic BC in SD rats. (A) Cystography and (B) external and internal surface of bladders after intravesical chemotherapy with PBS as a control, free HCPT, or R₉NG/HCPPT. (C) Evolution of body weight and (D) survival rate during the experiments. The scale bars represent (A) 1.0 cm and (B) 0.5 cm, respectively. Data are presented as mean ± standard deviation (*n* = 8). Supplementary 9. Figure S8: histopathology and

immunofluorescence of orthotopic BC in SD rats. (A) Histo-pathological (*i.e.*, H&E) and (B) immunofluorescence (*i.e.*, caspase-3 and Ki-67) analysis of tumor tissue sections after treatment with PBS as a control, free HCPT, or R₉NG/HCPT. The scale bars in (A) and (B) represent 0.5 cm and 100 μ m, respectively. The quantitative analysis of (C) caspase-3 and (D) Ki-67 expression after treatments with different HCPT formulations. Data are presented as mean $\pm$ standard deviation ($n = 3$; * $P < 0.05$, *** $P < 0.001$). (Supplementary Materials)

References

- [1] A. M. Kamat, M. Colombel, D. Sundi et al., "BCG-unresponsive non-muscle-invasive bladder cancer: Recommendations from the IBCG," *Nature Reviews Urology*, vol. 14, no. 4, pp. 244–255, 2017.
- [2] W. S. Tan, A. Panchal, L. Buckley et al., "Radiofrequency-induced thermo-chemotherapy effect versus a second course of bacillus Calmette-Guérin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance bacillus Calmette-Guérin therapy (HYMN): A phase III, open-label, randomised controlled trial," *European Urology*, vol. 75, no. 1, pp. 63–71, 2019.
- [3] J. D. Kelly, W. S. Tan, N. Porta et al., "BOXIT—A randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder (CRUK/07/004)," *European Urology*, vol. 75, no. 4, pp. 593–601, 2019.
- [4] J. Hedegaard, P. Lamy, I. Nordentoft et al., "Comprehensive transcriptional analysis of early-stage urothelial carcinoma," *Cancer Cell*, vol. 30, no. 1, pp. 27–42, 2016.
- [5] C. Berdik, "Unlocking bladder cancer," *Nature*, vol. 551, no. 7679, pp. S34–S35, 2017.
- [6] R. M. Davis, B. Kiss, D. R. Trivedi, T. J. Metzner, J. C. Liao, and S. S. Gambhir, "Surface-enhanced Raman scattering nanoparticles for multiplexed imaging of bladder cancer tissue permeability and molecular phenotype," *ACS Nano*, vol. 12, no. 10, pp. 9669–9679, 2018.
- [7] C. M. Caramella, S. Rossi, F. Ferrari, M. C. Bonferoni, and G. Sandri, "Mucoadhesive and thermogelling systems for vaginal drug delivery," *Advanced Drug Delivery Reviews*, vol. 92, pp. 39–52, 2015.
- [8] M. R. Kang, G. Yang, R. F. Place et al., "Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth," *Cancer Research*, vol. 72, no. 19, pp. 5069–5079, 2012.
- [9] Y. Y. Wang, S. K. Lai, J. S. Suk, A. Pace, R. Cone, and J. Hanes, "Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier," *Angewandte Chemie, International Edition*, vol. 47, no. 50, pp. 9726–9729, 2008.
- [10] S. Wiczkorek, A. Dallmann, Z. Kochovski, and H. G. Borner, "Advancing drug formulation additives toward precision additives with release mediating peptide interlayer," *Journal of the American Chemical Society*, vol. 138, no. 30, pp. 9349–9352, 2016.
- [11] J. Hao, G. Song, T. Liu et al., "In vivo long-term biodistribution, excretion, and toxicology of PEGylated transition-metal dichalcogenides MS₂ (M = Mo, W, Ti) nanosheets," *Advanced Science*, vol. 4, no. 1, article 1600160, 2017.
- [12] C. Douat, C. Aisenbrey, S. Antunes et al., "A cell-penetrating foldamer with a bio-reducible linkage for intracellular delivery of DNA," *Angewandte Chemie, International Edition*, vol. 54, no. 38, pp. 11133–11137, 2015.
- [13] B. P. Meloni, D. Milani, A. B. Edwards et al., "Neuroprotective peptides fused to arginine-rich cell penetrating peptides: Neuroprotective mechanism likely mediated by peptide endocytic properties," *Pharmacology and Therapeutics*, vol. 153, pp. 36–54, 2015.
- [14] N. Q. Shi and X. R. Qi, "Taming the wildness of "Trojan-Horse" peptides by charge-guided masking and protease-triggered demasking for the controlled delivery of antitumor agents," *ACS Applied Materials & Interfaces*, vol. 9, no. 12, pp. 10519–10529, 2017.
- [15] M. Li, S. Schlesiger, S. K. Knauer, and C. Schmuck, "A tailor-made specific anion-binding motif in the side chain transforms a tetrapeptide into an efficient vector for gene delivery," *Angewandte Chemie, International Edition*, vol. 54, no. 10, pp. 2941–2944, 2015.
- [16] N. Zhang, Z. Yan, X. Zhao, Q. Chen, and M. Ma, "Efficient mini-transporter for cytosolic protein delivery," *ACS Applied Materials & Interfaces*, vol. 8, no. 39, pp. 25725–25732, 2016.
- [17] A. A. Hakimi, E. Reznik, C. H. Lee et al., "An integrated metabolic atlas of clear cell renal cell carcinoma," *Cancer Cell*, vol. 29, no. 1, pp. 104–116, 2016.
- [18] H. Guo, W. Xu, J. Chen et al., "Positively charged polypeptide nanogel enhances mucoadhesion and penetrability of 10-hydroxycamptothecin in orthotopic bladder carcinoma," *Journal of Controlled Release*, vol. 259, pp. 136–148, 2017.
- [19] D. A. Zaharoff, B. S. Hoffman, H. B. Hooper et al., "Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12," *Cancer Research*, vol. 69, no. 15, pp. 6192–6199, 2009.
- [20] P. M. K. Westcott, K. D. Halliwill, M. D. To et al., "The mutational landscapes of genetic and chemical models of KRAS-driven lung cancer," *Nature*, vol. 517, no. 7535, pp. 489–492, 2015.
- [21] G. Aldrian, A. Vaissière, K. Konate et al., "PEGylation rate influences peptide-based nanoparticles mediated siRNA delivery in vitro and in vivo," *Journal of Controlled Release*, vol. 256, pp. 79–91, 2017.
- [22] X. R. Feng, J. X. Ding, R. Gref, and X. S. Chen, "Poly(β -cyclodextrin)-mediated polylactide-cholesterol stereocomplex micelles for controlled drug delivery," *Chinese Journal of Polymer Science*, vol. 35, no. 6, article 1932, pp. 693–699, 2017.
- [23] J. Chen, J. Ding, W. Xu et al., "Receptor and microenvironment dual-recognizable nanogel for targeted chemotherapy of highly metastatic malignancy," *Nano Letters*, vol. 17, no. 7, pp. 4526–4533, 2017.
- [24] J. F. Zhang, H. L. Xiong, J. L. Cao et al., "A cell-penetrating whole molecule antibody targeting intracellular HBx suppresses hepatitis B virus via TRIM21-dependent pathway," *Theranostics*, vol. 8, no. 2, pp. 549–562, 2018.
- [25] T. Y. Lin, Y. Li, Q. Liu et al., "Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer," *Biomaterials*, vol. 104, pp. 339–351, 2016.
- [26] W. Wei, Z. G. Yue, J. B. Qu, H. Yue, Z. G. Su, and G. H. Ma, "Galactosylated nanocrystallites of insoluble anticancer drug

- for liver-targeting therapy: An *in vitro* evaluation,” *Nanomedicine*, vol. 5, no. 4, pp. 589–596, 2010.
- [27] B. S. Lele and A. S. Hoffman, “Mucoadhesive drug carriers based on complexes of poly(acrylic acid) and PEGylated drugs having hydrolysable PEG-anhydride-drug linkages,” *Journal of Controlled Release*, vol. 69, no. 2, pp. 237–248, 2000.
 - [28] Y. Lee, T. E. Deelman, K. Chen, D. S. Y. Lin, A. Tavakkoli, and J. M. Karp, “Therapeutic luminal coating of the intestine,” *Nature Materials*, vol. 17, no. 9, pp. 834–842, 2018.
 - [29] J. Chen, J. Ding, Y. Wang et al., “Sequentially responsive shell-stacked nanoparticles for deep penetration into solid tumors,” *Advanced Materials*, vol. 29, no. 32, article 1701170, 2017.
 - [30] S. Futaki and I. Nakase, “Cell-surface interactions on arginine-rich cell-penetrating peptides allow for multiplex modes of internalization,” *Accounts of Chemical Research*, vol. 50, no. 10, pp. 2449–2456, 2017.
 - [31] A. J. Vandever, J. K. Fallon, R. Tighe, H. Sabzevari, J. Schlom, and J. W. Greiner, “Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor,” *Cancer Immunology Research*, vol. 4, no. 5, pp. 452–462, 2016.
 - [32] H. Guo, F. Li, W. Xu et al., “Mucoadhesive cationic polypeptide nanogel with enhanced penetration for efficient intravesical chemotherapy of bladder cancer,” *Advanced Science*, vol. 5, no. 6, article 1800004, 2018.
 - [33] R. Kinoshita, Y. Ishima, V. T. G. Chuang et al., “Improved anticancer effects of albumin-bound paclitaxel nanoparticle *via* augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer,” *Biomaterials*, vol. 140, pp. 162–169, 2017.
 - [34] N. Ma, P. Liu, N. He, N. Gu, F. G. Wu, and Z. Chen, “Action of gold nanospikes-based nanoradiosensitizers: Cellular internalization, radiotherapy, and autophagy,” *ACS Applied Materials & Interfaces*, vol. 9, no. 37, pp. 31526–31542, 2017.
 - [35] S. Cuylen, C. Blaukopf, A. Z. Politi et al., “Ki-67 acts as a biological surfactant to disperse mitotic chromosomes,” *Nature*, vol. 535, no. 7611, pp. 308–312, 2016.